CCGB(SZ:300138) Zheng Quan Zhi Xing·2025-08-26 23:09Core Viewpoint - The recent financial report of Morning Light Bio (300138) shows significant growth in revenue and net profit, indicating improved profitability and operational efficiency. Financial Performance - As of the end of the reporting period, the company's total revenue reached 3.658 billion yuan, a year-on-year increase of 4.77% [1] - The net profit attributable to shareholders was 215 million yuan, up 115.33% year-on-year [1] - In Q2, total revenue was 1.941 billion yuan, reflecting a 10.38% increase year-on-year, while net profit for the quarter was 105 million yuan, up 72.25% [1] - Gross margin improved to 13.86%, a year-on-year increase of 67.4%, and net margin rose to 6.05%, up 125.15% [1] - Total expenses (selling, administrative, and financial) amounted to 156 million yuan, accounting for 4.28% of revenue, a decrease of 0.44% year-on-year [1] Key Financial Ratios - Earnings per share (EPS) increased to 0.44 yuan, a rise of 131.58% year-on-year [1] - Operating cash flow per share reached 3.79 yuan, up 95.33% year-on-year [1] - The company's return on invested capital (ROIC) was 1.91%, indicating weak capital returns [1] - The debt-to-asset ratio for interest-bearing liabilities reached 56.97% [4] Business Model and Strategy - The company's performance is primarily driven by research and development, necessitating a thorough examination of the underlying drivers [3] - The company is focusing on the trend of replacing synthetic colors with natural colors, which presents significant opportunities in the natural color industry [7] Market Position and Investor Interest - Several funds have recently increased their holdings in Morning Light Bio, indicating growing investor interest [6] - The largest fund holding the company is Wan Jia Domestic Demand Growth Mixed Fund, with a scale of 530 million yuan [6]